Market: NMS |
Currency:
Address:
📈 NUCL Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
-
-
EPS Growth Range (1Y):
-
-
Net Income Growth Range (1Y):
-
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for NUCL
No earnings history available for this symbol.
📰 Related News & Research
-
Perma-Fix Environmental Services Inc. 2025 Annual Report: Nuclear Waste Management, PFAS Technology, and Business Overview
March 25, 2026
Perma-Fix Environmental Services, Inc. (PESI) 2025 Annual Re...
-
Oklo Inc. 2025 Annual Report: Aurora Powerhouses, Nuclear Fuel Recycling, and Growth Strategies in Clean Energy Industry
March 18, 2026
Oklo Inc. Annual Report 10-K: Key Investor Insights ...
-
China Isotope & Radiation Corporation and Zhonghe Headway Sign Strategic Cooperation Agreement with Maoming Government to Advance Nuclear Technology Industry in Guangdong 1
March 15, 2026
China Isotope & Radiation Corporation Enters Strategic Agree...
-
Global Leader in Safety Equipment Manufacturing for Law Enforcement, Military, and Nuclear Markets – Business Overview and Growth Strategy 45
March 11, 2026
Cadre Holdings, Inc. 2025 Annual Report: Key Insights for In...
-
Hennessy Capital Investment Corp. VII (HVII) 2025 Annual Report: Business Overview, Acquisition Criteria, and Proposed Merger with ONE Nuclear 55
March 7, 2026
Hennessy Capital Investment Corp. VII 2025 Annual Report – K...
-
PepGen Inc. Enhanced Delivery Oligonucleotide Platform: Advancing Oligonucleotide Therapeutics for Neuromuscular and Neurologic Diseases 3940414546
March 4, 2026
PepGen Inc. 10-K Report: Key Highlights for Investors ...
-
Lightbridge Corp Achieves Key Nuclear Fuel Milestones and Reports Strong Fiscal 2025 Financial Results
February 26, 2026
Lightbridge Corporation FY2025 Results & Business Update ...
-
Suzhou Ribo Life Science IPO: Leading the Future of siRNA Oligonucleotide Therapeutics – Company Overview, Pipeline, and Competitive Edge 1116272278
January 4, 2026
Suzhou Ribo Life Science Co., Ltd. IPO: Investor Analysis & ...
🔍 View more Reports